Showing 6611-6620 of 8237 results for "".
- ISHRS 2022 Practice Consensus Results: Hair Restoration Trendshttps://practicaldermatology.com/news/ishrs-2022-practice-consensus-results-hair-restoration-trends/2461192/The International Society of Hair Restoration Surgery (ISHRS) released resutls of a new member survey that found 68 percent of members performed an average of one procedure per patient in 2021 to achieve the desired hair restoration result. This represents a significant improvement, as ISHRS memb
- Curél Gives Back: Skincare Brand Supports Nurseshttps://practicaldermatology.com/news/curel-gives-back-skincare-brand-supports-nurses/2461187/Through Curél Cares, Curél will be donating to the American Nurses Foundation and treating several highly deserving nurses to an all-expenses-paid pampering trip to New York City. In addition, Curél will also sponsor the half-day American Nurses Associati
- Castle Biosciences Supports Patient-Focused Initiatives for Skin Cancer Awareness Monthhttps://practicaldermatology.com/news/castle-biosciences-supports-of-patient-focused-initiatives-for-skin-cancer-awareness-month/2461182/Castle Biosciences, Inc. will continue its ongoing collaboration with the Melanoma Research Foundation (MRF) and The Skin Cancer Foundation to support skin cancer research, education and advocacy, highlighting events during May, in recognition of Skin Cancer Awareness Month. “We a
- Healthy-appearing Lupus Skin Predisposed to Flares, Rasheshttps://practicaldermatology.com/news/healthy-appearing-lupus-skin-predisposed-to-flares-rashes/2461181/Normal-appearing skin of lupus patients contains the same inflammatory signals that are detected when the skin develops a rash – sometimes at even higher levels, according to a study in Science Translational Medicine. “This really starts to piece the puzzle together
- Pathologist Survey: Melanoma Is Overdiagnosedhttps://practicaldermatology.com/news/pathologist-survey-melanoma-is-overdiagnosed/2461180/Many pathologists agree that overdiagnosis of skin cancer happens, but don’t change diagnosis behavior, according to a new study. “Overdiagnosis is the diagnosis of disease that will not harm a person in their lifetime. If melanoma is being overdiagnosed, it means that too m
- Cutera Hosts AviClear Webinar This Weekhttps://practicaldermatology.com/news/cutera-hosts-aviclear-webinar-this-week/2461178/Cutera hosts the first webinar for AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, this week. Dermatologists Jeffrey S. Dover, MD, FRCPC and Julie C. Harper, MD will discuss the latest advancement in the treatment of acn
- ePatch Using Electrical Field Stimulation Shows Promise for Wound Healinghttps://practicaldermatology.com/news/epatch-using-electrical-field-stimulation-shows-promise-for-wound-healing/2461175/A “smart” flexible electric patch (ePatch) developed by a collaborative team from the Terasaki Institute for Biomedical Innovation promises to address the challenges posed by existing electrical field (EF) stimulation devices for wound healing and offers many uniquely advantageous fea
- Lumenis Has Launched triLift for Facial Stimulationhttps://practicaldermatology.com/news/lumenis-has-launched-trilift-for-facial-stimulation/2461173/Lumenis Be, Ltd., has launched triLift, a facial stimulation device targeting three aging elements—structure, contour, and texture—by treating the three tissue layers. The device affects the muscl
- Cutera to Celebrate AviClear Launch at ASLMShttps://practicaldermatology.com/news/cutera-to-celebrate-aviclear-launch-at-aslms/2461165/Cutera is celebrating the launch of AviClear, the first and only FDA cleared energy-based device for the treatment of mild, moderate, and severe acne, during the ASLMS meeting in San Diego. ASLMS attendees are invited to the celebration for the launch of AviClear on Thursday, April 28,
- TOOsonix System ONE-M BCC Clinical Trial Updatehttps://practicaldermatology.com/news/toosonix-system-one-m-bcc-clinical-trial-update/2461162/The first basal cell carcinoma (BCC) patients have been treated with TOOsonix A/S’s System ONE-M device. The TOOsonix high-intensity focused ultrasound (HIFU) delivers highly accurate doses of energy to focal points in a chosen depth. It operates at 20 MHz to